biostudies-literatureLatosinska ABundesministerium für Bildung und ForschungFIS/Fondos FEDERComunidad de Madrid en BiomedicinaAustrian Science Fund FWFInstituto de Salud Carlos IIIAgence Nationale de la RechercheHorizon 2020 Framework ProgrammeBundesministerium für Wirtschaft und KlimaschutzEuropean Health and Digital Executive AgencyEuropean Cooperation in Science and TechnologyHORIZON EUROPE Marie Sklodowska- Curie ActionsHORIZON EUROPE Marie Sklodowska-Curie Actions943https://www.ebi.ac.uk/biostudies/studies/S-EPMC12372250biostudies-literatureUnknown23(1)Chronic kidney disease (CKD) contributes to global morbidity and mortality. Early, targeted intervention can help mitigate its impact. CK273 is a urinary peptide classifier previously validated in a prospective clinical trial for the early detection of nephropathy. We hypothesized that drug-induced molecular changes in the urinary peptidome could be predicted in silico and guide selecting interventions for individual patients. The efficacy of the urinary peptidomic classifier CKD273 in predicting major adverse kidney events (≥ 40% decline in estimated glomerular filtration rate or kidney failure -median follow-up: 1.50 (95%CI 0.35, 5.0) years), was confirmed in a retrospective cohort of 935 participants. In silico prediction of treatment effects from four drug-based interventions (MineraloJournal of translational medicineIn silico prediction of optimal multifactorial intervention in chronic kidney disease.PMC12372250P2022/BMD-7223ANR-22-PERM-0002-06AC22/00027Grant-DOI 10.55776/I6464SPACKDc PMP21/00109101168626RICORS program to RICORS2040 (RD21/0005/0001)101101220CIFRACOR-CM101072828ZIMKK5560002AP3848011CA2116501EK2105C01EK2105B01EK2105A01KU2307I 6464Delles CGolovko IBeige JSiwy JRossing PNguyen TMNMayer GPersson FPeter KLatosinska AOrtiz ARupprecht HSchanstra JPMina IKStaessen JARychlik IKeller FGlorieux GClark ALCampbell AMischak HVlahou AfalseIn silico prediction of optimal multifactorial intervention in chronic kidney disease.Chronic kidney disease (CKD) contributes to global morbidity and mortality. Early, targeted intervention can help mitigate its impact. CK273 is a urinary peptide classifier previously validated in a prospective clinical trial for the early detection of nephropathy. We hypothesized that drug-induced molecular changes in the urinary peptidome could be predicted in silico and guide selecting interventions for individual patients. The efficacy of the urinary peptidomic classifier CKD273 in predicting major adverse kidney events (≥ 40% decline in estimated glomerular filtration rate or kidney failure -median follow-up: 1.50 (95%CI 0.35, 5.0) years), was confirmed in a retrospective cohort of 935 participants. In silico prediction of treatment effects from four drug-based interventions (Mineralo2025-01-01T00:00:00Z2025 Aug2026-05-08T10:50:51.036Z2026-05-03T03:05:54.901ZS-EPMC123722504084202610.1186/s12967-025-06977-3